Company NKMAX CO., Ltd.

Equities

A182400

KR7182400002

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per region

Sector Bio Therapeutic Drugs

End-of-day quote Korea S.E. Other stock markets 04:30:00 25/03/2024 am IST			5-day change	1st Jan Change
2,020 ^KRW	+9.54%		-.--%	-67.58%

16/05	NKMAX CO., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
17/04	NKMAX CO., Ltd. cancelled the transaction announced on October 20, 2023	CI

NKMAX Co., Ltd., formerly ATGen, is a Korea-based company principally engaged in the research, development, manufacturing and supply of biological products. The Company is involved in the production and sale of recombinant proteins, monoclonal antibodies, NK cell activity test kits, cell therapy products, and in the provision of other related services. The NK cell activity test kits are provided under the name of NK Vue. The Company distributes its products within domestic market and to overseas markets.

Number of employees: 134

KRW in Million	2022	Weight	2023	Weight	Delta
Reagent and Cancer Diagnostic Kits 100.0 %	11,263	100.0 %	10,769	100.0 %	-4.38%

KRW in Million	2022	Weight	2023	Weight	Delta
South Korea 55.0 %	6,865	61.0 %	5,920	55.0 %	-13.76%
North America 23.5 %	2,317	20.6 %	2,534	23.5 %	+9.40%
Europe 15.7 %	1,519	13.5 %	1,693	15.7 %	+11.46%
Asia 5.8 %	562	5.0 %	621	5.8 %	+10.51%

Managers	Title	Age	Since
Sang-Woo Park CEO	Chief Executive Officer	55	14/02/14
Jun-Yong Song DFI	Director of Finance/CFO	57	-
Yong-Hwan Cho COO	Chief Operating Officer	52	01/15/01
Jeong-Chan Lee AUD	Comptroller/Controller/Auditor	67	-
Kang-Yong Pierre SAM	Sales & Marketing	52	01/09/01

Members of the board	Title	Age	Since
Sang-Woo Park CEO	Chief Executive Officer	55	14/02/14
Yong-Man Kim BRD	Director/Board Member	58	13/19/13
Kang-Yong Pierre SAM	Sales & Marketing	52	01/09/01
Yong-Hwan Cho COO	Chief Operating Officer	52	01/15/01
Jeong-Heon Cha BRD	Director/Board Member	58	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	85,518,831	78,533,292 ( 91.83 %)	1,715 ( 0.002005 %)	91.83 %

Name	Equities	%	Valuation
Heung-ja Jin 0.4453 %	380,788	0.4453 %	573 082 ₩
Jin-woo Park 0.2410 %	206,094	0.2410 %	310 169 ₩
Jung-ah Min 0.0806 %	68,922	0.0806 %	103 727 ₩
Yong-Man Kim 0.0146 %	12,500	0.0146 %	18 812 ₩
Sang-Woo Park 0.006335 %	5,418	0.006335 %	8 154 ₩
NKMAX CO., LTD. 0.004011 %	3,430	0.004011 %	5 162 ₩
Kyung-deok Min 0.000578 %	494	0.000578 %	743 ₩

Name	Equities	%	Valuation
NKGen Biotech, Inc. 40.66%	10,120,612	40.66%	16,901,422 $

NKMAX Co., Ltd. (South korea)

1-6/F, Health Care Park 172 Dolma-ro

13605, Seongnam

http://www.nkvue.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
NKMAX CO., LTD.	-67.58%	124M
VERTEX PHARMACEUTICALS INCORPORATED	+16.49%	122B
REGENERON PHARMACEUTICALS, INC.	+21.73%	116B
ARGENX SE	+22.18%	27.03B
BIONTECH SE	-21.81%	20.36B
GENMAB A/S	-16.89%	16.43B
BEIGENE, LTD.	-18.81%	15.91B
WUXI APPTEC CO., LTD.	-44.74%	15.6B
SAREPTA THERAPEUTICS, INC.	+62.72%	14.94B
NEUROCRINE BIOSCIENCES, INC.	+3.09%	13.59B

Bio Therapeutic Drugs